ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug Therapy to Treat Minor Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00048815
Recruitment Status : Completed
First Posted : November 13, 2002
Results First Posted : May 10, 2018
Last Update Posted : May 10, 2018
Sponsor:
Collaborators:
National Institute of Mental Health (NIMH)
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Information provided by (Responsible Party):
Andrew A. Nierenberg, MD, Massachusetts General Hospital

November 8, 2002
November 13, 2002
June 17, 2014
May 10, 2018
May 10, 2018
February 2003
April 2007   (Final data collection date for primary outcome measure)
  • Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) [ Time Frame: Change from Baseline to Week 12 ]
    We expect that subjects with minor depression treated for 12 weeks with St. John's Wort or citalopram will have significantly greater reduction in depressive symptom severity than those treated with placebo. This will be measured by blind ratings on the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) which has a total score range from 0 to 84 with 0 being not depressed at all and 84 being the most depressed. The change will be calculated by subtracting the Week 12 score from the Baseline score.
  • Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment [ Time Frame: Change from Baseline to Week 12 ]
    We expect that subjects treated for Minor Depression for 12 weeks with either St. John's Wort or citalopram will have similar safety profiles to subjects treated with placebo, and will not differ by more than 20% in rates of adverse side effects (e.g., nausea, headache, insomnia, hypersomnia, diarrhea) from subjects treated with placebo. This was measured by the number of adverse events (physical symptoms) emerging or worsening during 12 weeks of treatment.
Not Provided
Complete list of historical versions of study NCT00048815 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Drug Therapy to Treat Minor Depression
Pharmacotherapy for Minor Depression
This 6-month study will compare the effectiveness of citalopram (Celexa®), hypericum (St. John's Wort), and placebo for the treatment of minor depression.

Minor depression is highly prevalent, causes substantial morbidity and disability, presents a serious risk factor for the development of major depressive disorder, yet is under recognized and under treated. Researchers have determined that patients with minor depression frequently seek treatment from general practitioners and are often treated with prescription antidepressants. There is a need to evaluate the effectiveness of St. John's Wort in the management of minor depression. If the proposed study demonstrates the efficacy of St. John's Wort and/or citalopram, it will suggest treatment paradigms that can be tested and applied in primary care settings.

Subjects participated in a 12-week double-blind randomized study comparing St. John's Wort, citalopram, and placebo. Subjects were recruited through clinical referrals and community advertising. Data were obtained at the baseline visit (just prior to randomization) and at postrandomization visits conducted at 2-week intervals for the next 12 weeks, for a modified intent-to-treat sample consisting of all 73 subjects with at least 1 post-randomization visit (evaluable sample).

Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Depression
  • Drug: Citalopram
    Established Selective Serotonin Reuptake Inhibitor antidepressant
    Other Name: Celexa, Cipramil
  • Drug: St. John's Wort
    Natural extract from the St. John's Wort plant.
    Other Name: Hypericum
  • Drug: Placebos
    Placebo pill
  • Active Comparator: citalopram
    Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
    Intervention: Drug: Citalopram
  • Experimental: St. John's Wort
    Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
    Intervention: Drug: St. John's Wort
  • Placebo Comparator: Placebo
    Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
    Intervention: Drug: Placebos
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
73
300
April 2007
April 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Minor Depression symptoms for at least 6 months
  • Endorse one of the DSM-IV "A" criteria for MDD and at least one other symptom of MDD or endorse both of the "A" criteria for MDD
  • Global Assessment of Functioning (GAF) score < 70
  • Short form health survey (SF-36) social functioning score <= 75% or an emotional role functioning score <= 67%
  • HAM-D-17 score 10-17, inclusive
  • Minor depression symptoms for at least 6 months

Exclusion Criteria:

  • Major depressive disorder (MDD) or dysthymia within the past year or in partial remission of MDD
  • At least a 12-week course of either citalopram at a minimum or 40 mg/day or St. John's Wort at a minimum of 900 mg/day during the current episode of depression
  • Previous intolerance to either citalopram or St. John's Wort or history of nonresponse to either citalopram at a minimum of 40 mg/day or St. John's Wort at a minimum of 900 mg/day for at least 12 weeks
  • Unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease
  • Uncontrolled seizure disorder
  • The following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last year or patients with a positive urine drug screen; schizophrenia; delusional disorder; psychotic disorders not elsewhere classified; bipolar disorder; bereavement; adjustment disorder; antisocial personality disorder; panic disorder, social phobia, generalized anxiety disorder (GAD), or obsessive compulsive disorder (OCD). Patients may have a lifetime diagnosis of an anxiety disorder as long as it is not current.
  • Mood-congruent or mood-incongruent psychotic features
  • Psychotropic drugs
  • Hypothyroidism
  • Investigational psychotropic drugs within the last year
  • Positive toxicology screen
  • Medications metabolized by the CYP3A4 system, where induction of this system poses a risk to the medical stability of the patient
  • Pregnancy or refusal to use a medically accepted method of contraception
  • Serious suicide or homicide risk
  • Psychotherapy beginning less than 3 months ago
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00048815
R01MH061758( U.S. NIH Grant/Contract )
R01MH061758 ( U.S. NIH Grant/Contract )
R01MH061757 ( U.S. NIH Grant/Contract )
R01MH061394 ( U.S. NIH Grant/Contract )
DSIR AT-SO
Yes
Not Provided
Not Provided
Andrew A. Nierenberg, MD, Massachusetts General Hospital
Massachusetts General Hospital
  • National Institute of Mental Health (NIMH)
  • National Center for Complementary and Integrative Health (NCCIH)
  • Office of Dietary Supplements (ODS)
Principal Investigator: Andrew A. Nierenberg, M.D. Massachusetts General Hospital
Massachusetts General Hospital
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP